Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone formulation adherence and satisfaction study in maintenance-phase schizophrenia
ChiCTR1900022966Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- May 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paliperidone and paliperidone palmitate in schizophrenia (3 arms), sponsored by The First Hospital of Hebei Medical University. Primary endpoints: Medication Adherence Rating Scale score and Medication Satisfaction Questionnaire score. Planned start May 2019; status: not yet recruiting.
02
Drugs
paliperidonepaliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR1900022966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022966.